This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| interleukin-12 | |
|---|---|
| Name | Interleukin-12 |
interleukin-12 is a heterodimeric cytokine produced by antigen-presenting cells that bridges innate and adaptive immunity. First characterized in studies involving National Institutes of Health-funded laboratories and described in journals associated with Nature (journal), Science (journal), and The Lancet, it has been central to research in infectious diseases, oncology, and autoimmunity. Investigations at institutions such as Harvard University, University of Cambridge, and Stanford University shaped understanding of its role in T cell differentiation and host defense.
The molecule comprises two subunits originally elucidated through structural biology studies involving teams from Max Planck Society and Cold Spring Harbor Laboratory. Early cloning efforts were reported by groups at Washington University in St. Louis and Imperial College London, which used techniques developed at Massachusetts Institute of Technology and the European Molecular Biology Laboratory. Crystallography and cryo-electron microscopy performed at facilities associated with Scripps Research Institute and Rutherford Appleton Laboratory resolved the heterodimeric arrangement, informing mutagenesis work from labs at University of California, San Francisco and University of Tokyo. Biosynthesis occurs in antigen-presenting cells influenced by signaling cascades characterized in studies from Johns Hopkins University and University of Pennsylvania.
Receptor interactions were mapped in collaborative projects between researchers at Yale University, Columbia University, and University of Oxford, revealing affinity determinants studied alongside research on Janus kinase family members and Signal transducer and activator of transcription 4. Pathway elucidation was advanced using models from National Cancer Institute and computational analyses from California Institute of Technology, while pharmacologic modulation was examined in clinical research at Mayo Clinic and Cleveland Clinic. Downstream transcriptional programs intersect with pathways characterized in work at University of Chicago and Karolinska Institute.
Functional studies conducted at Rockefeller University, Fred Hutchinson Cancer Center, and The Scripps Research Institute demonstrated roles in Th1 differentiation and natural killer cell activation, building on immunology frameworks from Pasteur Institute and Institut Curie. Animal model research at University of Toronto and Monash University implicated it in resistance to intracellular pathogens studied in Centers for Disease Control and Prevention collaborations. Comparative immunology and vaccine research at Bill & Melinda Gates Foundation-funded centers linked its activity to adjuvant effects explored by teams at London School of Hygiene & Tropical Medicine and Karolinska Institutet.
Transcriptional and post-transcriptional regulation was parsed in genetic studies from Broad Institute and epigenetics labs at Wellcome Trust Sanger Institute. Cytokine milieu effects were characterized in experiments at University of California, Berkeley and Imperial College London, while environmental modulation and microbial triggers were investigated in projects involving World Health Organization partnerships and field sites supported by Centers for Disease Control and Prevention. Regulatory networks intersect with pathways studied at National Institute of Allergy and Infectious Diseases and genomic consortia including 1000 Genomes Project investigators.
Clinical research spanning Mayo Clinic, Cleveland Clinic, and oncologic centers such as Memorial Sloan Kettering Cancer Center linked dysregulated expression to autoimmune disorders evaluated in cohorts from Johns Hopkins Hospital and infectious disease outcomes tracked by Centers for Disease Control and Prevention. Associations with malignancies were explored in multicenter trials coordinated by National Cancer Institute and international consortia including researchers from Dana-Farber Cancer Institute and MD Anderson Cancer Center. Epidemiologic correlations were analyzed in studies involving World Health Organization surveillance and population cohorts at University College London.
Biotechnology and pharmaceutical efforts at companies collaborating with Genentech, Pfizer, and Novartis advanced clinical translation, including engineered cytokine therapies and antibody-based modulators tested in trials overseen by regulatory agencies such as Food and Drug Administration and European Medicines Agency. Adoptive immunotherapy strategies integrating knowledge from University of Pennsylvania and CAR-T programs at National Institutes of Health leveraged insights from earlier vaccine research at Bill & Melinda Gates Foundation. Ongoing drug development involves partnerships among academic centers like Stanford University and industry collaborators at GlaxoSmithKline and AstraZeneca.
Category:Cytokines